Clinical Trials Logo

Clinical Trial Summary

The goal of this prospective study is to evaluate the role of cardiovascular magnetic resonance (CMR) in patients with suspected non-ST elevation myocardial infarction (NSTEMI). The main endpoint is the reclassification rate, defined as the number of patients in whom the information provided by pre-angiography CMR affects the revascularization strategy or the final diagnosis. Participants will undergo to CMR before invasive coronary angiography (ICA).


Clinical Trial Description

All patients with NSTEMI eligible for the study undergo CMR prior to ICA. To avoid any delay in patients' treatment all examination will be analyzed by local trained staff at each center. All patients will thereafter undergo ICA and the standard of care (SOC) decision-making on revascularization strategy and diagnosis will be declared by the treating physician, which will be blinded to the participation of the patients in the study and about CMR results. The treating physician will also declare patient's next management according to ICA results. After having declared the diagnosis, the treating physician will then be informed about the CMR findings. Therefore, according to CMR results the treating physician may eventually modify the initial diagnosis and management. Treatment plan modifications include difference in the identification of the culprit lesion, referring the patient to medical therapy instead of a revascularization procedure or viceversa, switching from a percutaneous to a surgical revascularization procedure or viceversa, or need for further cardiac or non-cardiac investigations. Initial diagnosis includes confirmed NSTEMI or all other possible alternative diagnosis and proposed additional diagnostic examination(s) for further differential diagnosis. The CMR-modified SOC (CMR-SOC) and diagnosis made considering CMR results will be collected. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05751057
Study type Interventional
Source Cardiocentro Ticino
Contact Anna Giulia Pavon, MD
Phone 0041 091 811 5371
Email annagiulia.pavon@eoc.ch
Status Recruiting
Phase N/A
Start date December 14, 2022
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT03606330 - Systemic, Pancoronary and Local Coronary Vulnerability
Completed NCT04223986 - Prehospital Risk Stratification in Acute Coronary Syndromes N/A
Recruiting NCT03863327 - EKG Criteria and Identification of Acute Coronary Occlusion
Recruiting NCT03405207 - Vitamin D Deficiency Treatment Outcomes After Non-ST-Segment Elevation Myocardial Infarction Phase 2
Active, not recruiting NCT01864031 - The Role of Alcohol Consumption in the Aetiology of Different Cardiovascular Disease Phenotypes: a CALIBER Study N/A
Recruiting NCT03621111 - A Trial on the Role of Community Pharmacist in Improving Adherence and Clinical Outcomes in Post-Infarction N/A
Completed NCT03390270 - Risk-score Based ICU Triage
Recruiting NCT03778554 - Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction Phase 4
Recruiting NCT04788186 - Beta Blocker De-prescription Following Coronary Artery Bypass Graft Surgery (BEEFBURGER Trial). Phase 4
Terminated NCT03048019 - Antiplatelet Effects of Tirofiban vs. Cangrelor N-STEMI Patients Undergoing Percutaneous Coronary Intervention
Recruiting NCT02126202 - Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes Phase 4
Terminated NCT04912141 - Prevention of Acute Kidney Injury in Patients With NSTEMI Phase 2